INTELLIGENT BIO SOLUTIONS INC.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
INBS$1.97+11.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
| Convertible preferred stock · Common stock · Treasury stock · Additional paid-in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’ | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · income (loss) · interest · equity | ||||||||||||
| Balance, June 30, 2024 | - | $ | - | 3,456,000 | $34,557 | (116) | $(1) | $60,971,740 | $(51,964,332) | $(712,614) | $(146,159) | $8,183,191 |
| Issuance of common stock upon cashless exercise of warrants | - | - | 793,930 | 7,939 | - | - | - | - | - | - | 7,939 | |
| Stock awards issued to employees | - | - | 99,500 | 995 | - | - | 189,050 | - | - | - | 190,045 | |
| Issuance of restricted stock to vendors | - | - | 11,162 | 112 | - | - | 11,888 | - | - | - | 12,000 | |
| Issuance of common stock, net of issuance costs | - | - | 17,167 | 172 | - | - | 34,339 | - | - | - | 34,511 | |
| Foreign currency translation gain | - | - | - | - | - | - | - | - | 216,355 | - | 216,355 | |
| Net loss | - | - | - | - | - | - | - | (2,685,633) | - | (9,166) | (2,694,799) | |
| Balance, September 30, 2024 | - | - | 4,377,759 | 43,775 | (116) | (1) | 61,207,017 | (54,649,965) | (496,259) | (155,325) | 5,949,242 | |
| Issuance of restricted stock to vendors | - | - | 8,109 | 81 | - | - | 11,919 | - | - | - | 12,000 | |
| Issuance of common stock, net of issuance costs | - | - | 421,200 | 4,212 | - | - | 637,896 | - | - | - | 642,108 | |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | (143,165) | - | (143,165) | |
| Net loss | - | - | - | - | - | - | - | (2,249,470) | - | (7,327) | (2,256,797) | |
| Balance, December 31, 2024 | - | - | 4,807,068 | 48,068 | (116) | (1) | 61,856,832 | (56,899,435) | (639,424) | (162,652) | 4,203,388 | |
| Issuance of restricted stock to vendors | - | - | 4,706 | 47 | - | - | 11,953 | - | - | - | 12,000 | |
| Issuance of common stock upon cashless exercise of warrants | - | - | 625 | 6 | - | - | (6) | - | - | - | - | |
| Issuance of common stock, net of issuance costs | - | - | 1,981,996 | 19,820 | - | - | 3,143,225 | - | - | - | 3,163,045 | |
| Foreign currency translation gain | - | - | - | - | - | - | - | - | 116,007 | - | 116,007 | |
| Net loss | - | - | - | - | - | - | - | (2,543,526) | - | (7,148) | (2,550,674) | |
| Balance, March 31, 2025 | - | - | 6,794,395 | $67,941 | (116) | $(1) | $65,012,004 | $(59,442,961) | $(523,417) | $(169,800) | $4,943,766 | |
| Convertible preferred stock · Common stock · Treasury stock · Additional paid-in · Accumulated · Other comprehensive · Non- controlling · Total shareholders’ | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · income (loss) · interest · equity | ||||||||||||
| Balance, June 30, 2023 | - | $ | - | 194,200 | $1,942 | (116) | $(1) | $46,180,112 | $(41,807,573) | $(575,496) | $(111,986) | $3,686,998 |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | (18,016) | - | (18,016) | |
| Net loss | - | - | - | - | - | - | - | (2,425,204) | - | (7,220) | (2,432,424) | |
| Balance, September 30, 2023 | - | - | 194,200 | 1,942 | (116) | (1) | 46,180,112 | (44,232,777) | (593,512) | (119,206) | 1,236,558 | |
| Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs | 5,728,723 | 57,287 | 186,018 | 1,860 | - | - | 3,727,017 | - | - | - | 3,786,164 | |
| Conversion of convertible preferred shares into common stock | (5,728,723) | (57,287) | 477,394 | 4,774 | - | - | 52,513 | - | - | - | - | |
| Conversion of holdback Series C Preferred Stock into common stock | - | - | 6,248 | 62 | - | - | 32,700 | - | - | - | 32,762 | |
| Issuance of common stock upon cashless exercise Series F warrants | - | - | 612,182 | 6,122 | - | - | (6,122) | - | - | - | - | |
| Foreign currency translation gain | - | - | - | - | - | - | - | - | 75,133 | - | 75,133 | |
| Net loss | - | - | - | - | - | - | - | (1,969,641) | - | (6,742) | (1,976,383) | |
| Balance, December 31, 2023 | - | $ | - | 1,476,042 | $14,760 | (116) | $(1) | $49,986,220 | $(46,202,418) | $(518,379) | $(125,948) | $3,154,234 |
| Reverse stock split rounding adjustment | - | - | 47,501 | 475 | - | - | (475) | - | - | - | - | |
| Issuance of common stock upon cash exercise of Series E warrants | - | - | 629,409 | 6,291 | - | - | 1,645,207 | - | - | - | 1,651,498 | |
| Issuance of restricted stock to vendors | - | - | 42,760 | 428 | - | - | 204,393 | - | - | - | 204,821 | |
| Issuance of common stock upon cashless exercise of Series F warrants | - | - | 42,904 | 429 | - | - | - | - | - | - | 429 | |
| Issuance of common stock, Series I, H1 and H2 warrants, net of issuance costs | - | - | 675,183 | 6,752 | - | - | 9,110,829 | - | - | - | 9,117,581 | |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | (144,026) | - | (144,026) | |
| Net loss | - | - | - | - | - | - | - | (2,977,667) | - | (9,098) | (2,986,765) | |
| Balance, March 31, 2024 | - | $ | - | 2,913,799 | $29,135 | (116) | $(1) | $60,946,174 | $(49,180,085) | $(662,405) | $(135,046) | $10,997,772 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.